Antitumor Activity Shown for 2ME2 and Analogs in Preclinical Lung Cancer Models
PanzemÂ® NCD Demonstrates Dose-Dependent Increase in Survival
July 06, 2005
ROCKVILLE, MD, July 6—EntreMed, Inc. (Nasdaq: ENMD) today announced the presentation of results in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) preclinical models for its lead compound, 2-methoxyestradiol (2ME2 or PanzemÂ® NCD). EntreMed collaborators presented results from these studies during the 11th World Conference on Lung Cancer held in Barcelona, Spain, July 3-6, 2005.
Results demonstrated that 2ME2 and 2ME2 analogs effectively inhibited the in vitro growth of 19 distinct NSCLC and SCLC cell lines. Moreover, when evaluated in vivo, PanzemÂ® NCD demonstrated a statistically significant, dose-dependent increase in survival in an orthotopic animal model of NSCLC.
2ME2 is an orally active small molecule that attacks tumor cells through multiple mechanisms of action including inducing apoptosis, inhibiting angiogenesis, and disrupting microtubules. Analogs of 2ME2, developed by EntreMed scientists by modifying its chemical structure, have demonstrated enhanced antitumor and antiangiogenic properties and improved metabolism while retaining 2ME2’s multiple mechanisms of action.
Daniel Chan, Ph.D., Associate Professor, Division of Medical Oncology, University of Colorado Health Science Center and principal investigator on the study commented, “These data are encouraging and indicate the potential of 2ME2 and its new analogs for treating non-small cell lung cancer and small cell lung cancer in humans.”
Carolyn F. Sidor, M.D., M.B.A, EntreMed Vice President and Chief Medical Officer, commented on the presentation, “PanzemÂ® NCD and the 2ME2 analog program are key components of EntreMed’s drug candidate pipeline. These data support the potential role of PanzemÂ® NCD and its analogs in the treatment of human lung cancers. EntreMed is currently in Phase 1b studies with PanzemÂ® NCD in patients with advanced cancers and we anticipate the commencement of Phase II studies this year.”
EntreMed, Inc. (Nasdaq: ENMD) is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. PanzemÂ® (2-methoxyestradiol or 2ME2), the Company’s lead drug candidate, is currently in clinical trials for cancer, as well as in preclinical development for non-oncology indications. EntreMed’s goal is to develop and commercialize new compounds based on the Company’s expertise in angiogenesis, cell cycle regulation and inflammation—processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company’s website at http://www.entremed.com and in various filings with the Securities and Exchange Commission.
Forward Looking Statements
This release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act with respect to the outlook for expectations for future financial or business performance, strategies, expectations and goals. Forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Forward-looking statements speak only as of the date they are made, and no duty to update forward-looking statements is assumed. Actual results could differ materially from those currently anticipated due to a number of factors, including those set forth in Securities and Exchange Commission filings under “Risk Factors,” including risks relating to the need for additional capital and the uncertainty of additional funding; the early-stage products under development; uncertainties relating to clinical trials; success in the clinical development of any products; dependence on third parties; future capital needs; and risks relating to the commercialization, if any, of the Company’s proposed products (such as marketing, safety, regulatory, patent, product liability, supply, competition and other risks).
CASI Pharmaceuticals, Inc.